Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Russian oligarch Roman Abramovich 'negotiated humanitarian corridors from Mariupol and saved the lives of Ukrainian civilians' Kyiv official says
First ore delivered at Gudai-Darri iron ore mine in the Pilbara
Rio Tinto has delivered first ore from the Gudai-Darri iron ore mine as the company brings online its first greenfield mine in the Pilbara, Western Australia, in more than a decade. Gudai-Darri will help underpin future production of the company's flagship Pilbara Blend (TM) product.
The first autonomous AutoHaul(TM) trains loaded with ore from Gudai-Darri's process plant have travelled the new 166-kilometre rail line that connects to Rio Tinto's existing rail and port infrastructure. Production from the mine will continue to ramp up through the remainder of this year and is expected to reach full capacity during 2023.
Since ground was broken in April 2019, more than 14 million workhours have resulted in the movement of over 20 million cubic metres of earth, batching and placement of 35,000 cubic metres of concrete, and the installation of 10,000 tonnes of steel. The development of Gudai-Darri supported more than 3,000 jobs during the construction and design phase. The mine will support around 600 ongoing permanent roles.
With an expected life of more than 40 years and an annual capacity of 43 million tonnes, Gudai-Darri will underpin future production of Pilbara Blend (TM) product. A feasibilty study to support an expansion of this new hub is also progressing.
The mine's commissioning and ramp-up is expected to increase Rio Tinto's iron ore production volumes and improve product mix from the Pilbara in the second half of this year. Full-year shipments guidance for 2022 remains at 320 to 335 million tonnes (100% basis) subject to risks around the ramp up of new mines, weather and management of cultural heritage.
The capital cost for the mine is estimated to be $3.1 billion (A$4.3 billion). As disclosed in February, the company's replacement projects in the Pilbara, including Gudai-Darri, were subject to potential capital increases of approximately 15% due to ongoing COVID-19 restrictions, including labour access and supply chain quality issues. Group capital expenditure guidance for 2022 is unchanged at around $8 billion.
Rio Tinto Iron Ore Chief Executive Simon Trott said "The commissioning of Gudai-Darri represents the successful delivery of our first greenfield mine in over a decade, helping to support increased output of Pilbara Blend , our flagship product . It sets a new standard for Rio Tinto mine developments through its deployment of technology and innovation to enhance productivity and improve safety.
"I'd like to acknowledge the support of the Traditional Owners, the Banjima People, on whose country Gudai-Darri is situated. We have worked closely with the Banjima People to progress this project and we look forward to continuing to actively partner with them into the future."
Rio Tinto Chief Technical Officer Mark Davies said "The safe and successful delivery of Gudai-Darri, in the midst of a global pandemic, is testament to the resilience and har
I had signed up for company announcements from companies house for poolbeg and I got 7 today
Thank you for your reply
Another companies house announcement of a 75 per cent or more holding in company
Cessation of Cathal Friel as a person with significant control on 30 May 2022
Cessation of Ian O'connell as a person with significant control on 30 May 2022.
Lots of companies house announcements today, does anyone know what they mean
Vast Resources plc, the AIM-listed mining company, announces that further to the announcement made on 3 May 2022 regarding the non legally binding verbal assurance from Atlas Special Opportunities LLC ("Atlas") of no further conversions the Company has received a notice from Atlas that it elects to convert Bonds of USD 500,000 nominal value in accordance with the terms of the Bond Issuance Deed announced on 24 October 2019. The Company can confirm that it has satisfied the exercise of the Conversion Rights through the issue of 151,260,080 ordinary shares of 0.1 pence each in the Company ('Ordinary Shares') at a price of 0.27 pence per Ordinary Share.
The Company remains confident about the finalisation of the legal documentation process for the refinancing of the outstanding bonds currently $4,150,000.
Application will be made to the London Stock Exchange for 151,260,080 new Ordinary Shares to be admitted to trading on the AIM Market with admission expected to occur on or around 6 May 2022 ('Admission'). The issued new Ordinary Shares will rank pari passu in all respects with existing Ordinary Shares.
Following Admission of the new Ordinary Shares the issued ordinary share capital of Vast will consist of 760,512,143 Ordinary Shares. There are no Ordinary Shares held in treasury. 760,512,143 represents the total number of voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change in their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
I took the 5.9p per share and the money is in my ii account today
British-made components have been found in Russian weapons systems in Ukraine, triggering an investigation by the UK government.
High-tech UK parts for jamming systems and military radios were discovered as experts picked through hardware abandoned by Russian forces.
One Borisoglebsk-2 mobile jamming system contained components made in the UK, US, Germany, South Korea, Taiwan and the Netherlands.
I received a letter from iii
97 now
I bought £10,000 worth on ii
It looks like someone bought £65,000 worth of Poolbeg shares this morning
It looks like someone has a 65k buy, over 700,000 shares price 9.25
Also has Poolbeg on the list of 12 to follow
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan plc, has signed a GBP5m influenza human challenge study contract with a biotech company developing an antiviral drug for protection against respiratory viral infections.
The study, which is expected to commence in H2 2022, will test and assess the efficacy of a single dosing regimen of the client's antiviral drug, with healthy adult volunteers, using the hVIVO Influenza human challenge study model. Conducted at hVIVO's state-of-the-art facilities in London, Open Orphan expects the majority of revenues to be recognised in 2022.
Respiratory tract infections are infections of parts of the body involved in breathing, such as the sinuses, throat, airways or lungs and are often caused by viruses such as influenza. Seasonal influenza causes significant morbidity and mortality each year and a pandemic influenza continues to pose a worldwide threat. Influenza is a serious global health threat with an estimated 1 billion cases per year, 3-5 million severe cases and 290,000 - 650,000 deaths per year. Healthy volunteer human challenge studies of wild-type influenza play a major role in the development of vaccines and therapeutics against influenza.
hVIVO has been studying influenza for over 20 years and conducting influenza human challenge studies with its flu disease models for more than 15 years. hVIVO has conducted numerous flu challenge studies for a range of industry, governmental and academic clients, making its models the most well-used commercial flu disease models available on the market. hVIVO also has expertise in safely conducting challenge studies across a range of respiratory viruses, including various strains of Influenza, Respiratory Syncytial Virus (RSV) and human Rhinovirus HRV (common cold virus), malaria, and asthma. In October 2020, this expanded to include the SARS-CoV-2 virus.
Cathal Friel, Executive Chairman of Open Orphan, said : "We are delighted to be working with this biotech client to assess the efficacy of their antiviral product which has the potential to be an important treatment against respiratory viral infections, using the hVIVO Influenza human challenge study model .
"We have now signed contracts for 95% of our 2022 forecasted revenues. This is the fourth Influenza human challenge study that we have signed in 2021 and coupled with the contract wins that we have seen in other disease areas, this further underlines the growing interest in respiratory and infectious diseases within the pharmaceutical and biotechnology industries, which we expect to continue over the coming years.
"Additionally, the continued damaging effects of the COVID-19 pandemic have underlined the need for increased pandemic preparedness in relation to other potential pandemic infectious diseases, such a
Orph just have
Over 10 million pounds
RNS Number : 1989V
Open Orphan PLC
10 December 2021
10 December 2021
Open Orphan plc
("Open Orphan" or the "Company")
$13.4m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan plc, has signed a $13.4m contract with a US-based biotechnology company to test its novel antiviral candidate using the hVIVO Influenza Human Challenge Study Model.
The study is expected to commence in H2 2022 and will be conducted at hVIVO's state-of-the-art quarantine facilities in London. The Company expect the majority of revenues to be recognised in 2022.
The Company expects to sign an increasing number of contracts in this area as the global pandemic has highlighted the increased investment needed from governments and Big Pharma to develop effective, novel treatments for a range of infectious diseases that have potential to cause the next pandemic. Influenza is one such disease, with emergences of flu pandemics impossible to predict. Symptoms of influenza may be mild or cause severe disease, or in certain cases, death. Influenza is a serious global health threat with an estimated 1 billion cases per year, 3-5 million severe cases and 290,000 - 650,000 deaths per year.
hVIVO has two decades of experience and expertise in safely conducting challenge studies across a range of respiratory viruses, including various strains of influenza, respiratory syncytial virus (RSV), human rhinovirus (HRV - common cold virus), malaria, and asthma. In October 2020, this expanded to include the SARS-CoV-2 virus.
Cathal Friel, Executive Chairman of Open Orphan, said : " We are delighted to announce this significant challenge study contract valued at over GBP10m, with a US-based biotechnology client testing its highly promising influenza antiviral candidate. This contract demonstrates the Company's continued ability to convert its leading portfolio of challenge study models into substantial contracts, with signed contracts across a number of our challenge study models including RSV, asthma, hRV, and flu in the clinic next year. This underlines our market position as the world leader in the testing of vaccines, antivirals and respiratory products using human challenge trials.
"The recent emergence of the Omicron variant has illustrated the threat of pandemic infectious diseases, and as a result, pharma companies globally are looking to address the next cohort of infectious diseases which have potential to reach pandemic level, and are developing new therapeutics to help tackle them. Influenza is high on this list, and we expect to sign more contracts of this type as the infectious disease market grows exponentially in the coming years to be worth $250 billion by 2025. "
The information contained within this announcement is de
Just seen a trade at 12.26 for 173k shares at 23p